XML 197 R191.htm IDEA: XBRL DOCUMENT v3.20.1
Reportable segments (Details 1) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Statement [Line Items]      
Revenue $ 1,943,655 $ 2,265,803 $ 2,157,323
Cost of sales (1,383,603) (1,485,631) (1,394,822)
Gross profit 560,052 780,172 762,501
Other incomes by function 18,218 32,048 17,827
Administrative expenses (117,180) (118,126) (101,171)
Other expenses by function (25,995) (36,907) (53,600)
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 (1,057) 2,967 (8,038)
Other gains (losses) (383) 6,404 543
Financial income 26,289 22,533 13,499
Finance costs (76,939) (57,807) (50,124)
interest in the profit or loss of associates and joint ventures accounted for by the equity method 9,786 6,351 14,452
Exchange differences (2,169) (16,597) (1,299)
Profit (loss) before taxes 390,622 621,038 594,590
Income tax expense 110,019 178,975 166,173
Profit (loss) 280,603 442,063 428,417
Specialty plant nutrients [Member]      
Statement [Line Items]      
Revenue 723,920 781,751 697,251
Cost of sales (573,808) (613,267) (555,356)
Gross profit 150,112 168,484 145,779
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 150,112 168,484 141,895
Income tax expense 0 0 0
Profit (loss) 150,112 168,484 145,779
Iodine and its derivatives [Member]      
Statement [Line Items]      
Revenue 371,020 324,972 231,144
Cost of sales (230,468) (217,464) (199,808)
Gross profit 140,552 107,508 39,846
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 140,552 107,508 52,315
Income tax expense 0 0 0
Profit (loss) 140,552 107,508 52,315
Lithium and its derivatives [Member]      
Statement [Line Items]      
Revenue 505,714 734,801 644,573
Cost of sales (306,250) (316,875) (189,242)
Gross profit 199,464 417,926 339,011
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 199,464 417,926 339,011
Income tax expense 0 0 0
Profit (loss) 199,464 417,926 455,331
Industrial chemicals [Member]      
Statement [Line Items]      
Revenue 94,875 108,267 135,578
Cost of sales (63,590) (72,964) (91,753)
Gross profit 31,285 35,303 36,759
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 31,285 35,303 43,825
Income tax expense 0 0 0
Profit (loss) 31,285 35,303 36,759
Potassium [Member]      
Statement [Line Items]      
Revenue 212,151 267,474 403,323
Cost of sales (176,199) (217,386) (313,690)
Gross profit 35,952 50,088 43,846
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 35,952 50,088 65,636
Income tax expense 0 0 0
Profit (loss) 35,952 50,088 65,636
Other products and services [Member]      
Statement [Line Items]      
Revenue 35,975 48,538 62,238
Cost of sales (33,288) (47,675) (44,973)
Gross profit 2,687 863 5,796
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other gains (losses) 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
interest in the profit or loss of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Profit (loss) before taxes 2,687 863 5,796
Income tax expense 0 0 0
Profit (loss) 2,687 863 5,796
Corporate unit [Member]      
Statement [Line Items]      
Revenue 0 0 0
Cost of sales 0 0 0
Gross profit 0 0 0
Other incomes by function 18,218 32,048 15,202
Administrative expenses (117,180) (118,126) (88,436)
Other expenses by function (25,995) (36,907) (82,533)
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 (1,057) 2,967 7,198
Other gains (losses) (383) 6,404 679
Financial income 26,289 22,533 10,129
Finance costs (76,939) (57,807) (57,498)
interest in the profit or loss of associates and joint ventures accounted for by the equity method 9,786 6,351 13,047
Exchange differences (2,169) (16,597) 460
Profit (loss) before taxes (169,430) (159,134) (181,752)
Income tax expense (110,019) (178,975) (132,965)
Profit (loss) $ (279,449) $ (338,109) $ (314,717)